Oxford Gene Technology (OGT) has acquired Sense Proteomic to pad its biomarker discovery activities. Sense Proteomic uses a functional protein array technology for its research activities.
Sense Proteomic has reportedly identified autoantibody signatures for diagnosis and prognosis. The discovered autoantibodies may also be used to identify stage of a disease by monitoring the changes in production during disease progression, to monitor the response to therapeutic interventions, and to improve clinical outcomes by the stratification of patients for clinical trials and treatment. The firm reports that it has already found biomarker panels for several diseases including prostate cancer and systemic lupus erythematosus.
“This deal combined with our recent development of an ultrahigh-throughput DNA microarray facility gives OGT a unique blend of genomic and proteomic technologies and will lead to the development of biomarkers with profound clinical significance,” notes Mike Evans, OGT’s CEO.